BCL2L1 and myeloid sarcoma: In MS, BCL2L1 (B-cell lymphoma 2-like 1)-Doxorubicin (Importance 8.62) suggests apoptosis modulation to mitigate immune-driven neuronal damage, targeting mitochondrial-mediated inflammatory pathways.